Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma
Journal of Cancer Research and Clinical Oncology · 16.04.2024 · 150 (4)
DOI: 10.1007/s00432-024-05719-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 16.04.2024. Verfasst von Zichen Qiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-…. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Head and Neck Neoplasms, Carcinoma, Leukopenia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The objective of the study was to assess the effectiveness and toxicity of platinum-based adjuvant chemoradiotherapy (POCRT) in comparison to postoperative radiotherapy (PORT) in patients with head and neck adenoid cystic carcinoma (HNACC). Materials and methods This retrospective study analyzed patients diagnosed with HNACC at our center between January 2010 and April 2020. A 1:1 propensity score matching method was used to create a matched cohort.
Results
In this study, 206 patients were analyzed, with 147 patients (71.4%) receiving postoperative radiotherapy (PORT) and 59 patients (28.6%) receiving POCRT. Twenty-one patients experienced local–regional failure. The 3-, 5-, and 10-yr local–regional control (LRC) rate for the cohort were 92.0%, 90.6%, and 86.9%, respectively. In both the entire cohort and the matched cohort, the POCRT group exhibited superior LRC compared to the PORT group (Gray's test, all P < 0.05*). Multivariate analysis identified adjuvant concurrent chemotherapy as an independent prognostic factor for LRC (Competing risks regression, HR = 0.144, 95% CI 0.026–0.802, P = 0.027*). In addition, the POCRT group had higher incidences of upper gastrointestinal toxicity and hematologic toxicities, including leukopenia, neutropenia, and anemia (all P < 0.05*).
Conclusion
In terms of reducing locoregional failures in HNACC patients, POCRT may potentially offer a more effective therapeutic approach than using PORT alone, although it also entails an augmented burden of treatment-related toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Yuexiu District,…
- Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tong Zi Po Road, Changsha, 410013, People's Republic of China.
Zitieren
APA
Qiu, Z., Wu, Z., Zhou, X., Lin, M., Su, Y., & Tao, Y. (2024). Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma. Journal of Cancer Research and Clinical Oncology, 150(4). https://doi.org/10.1007/s00432-024-05719-0
Vancouver
Qiu Z, Wu Z, Zhou X, Lin M, Su Y, Tao Y. Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma. Journal of Cancer Research and Clinical Oncology. 2024;150(4). doi:10.1007/s00432-024-05719-0
BibTeX
@article{Qiu2024,
author = {Qiu, Zichen and Wu, Zheng and Zhou, Xiong and Lin, Minchuan and Su, Yong and Tao, Yalan},
title = {Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {4},
doi = {10.1007/s00432-024-05719-0}
}
EUVIMED